Relief for Helixmith’s management as voting at recent shareholders' meeting failed to remove top executives, including the South Korean biotech’s founder and CEO, following recent setbacks. But the future of the board may now depend largely on the success of the ongoing clinical trials for lead assets and stock price recovery.

Comirnaty and Spikevax to get EU label update on cardiac safety, Japanese filing for REGEN-COV, plus vaccine progress for ReiThera and Genexine.

Plus deals involving Scynexis/Hansoh, Cend/Qilu, Apollomics/Edison, Apollomics/Iterion, Apollomics/Nuance, Aerami/Chance, Antibe/Nuance, Ildong/Arbormed

Plus Takeda starts vaccine trial in Japan and South Korea clears Celltrion's antibody therapeutic.